drugset / Trial / NCT05068674
Human Embryonic Stem Cell-Derived Cardiomyocyte Therapy for Chronic Ischemic Left Ventricular Dysfunction
Phase 1
Recruiting
18 enrolled
Joseph C. Wu
California Institute for Regenerative Medicine (CIRM) · collab
RandomizedSequentialOpen-labelTreatment
Summary
This clinical study will utilize a new cell therapy approach (Human embryonic stem cells derived cardiomyocytes or hESC-CMs) to improve survival and cardiac function in patients with chronic left ventricular dysfunction secondary to MI (Myocardial Infarction).
Timeline
- Start
- 2022-03-22
- Primary completion
- 2028-10
- Completion
- 2028-10
Drugs
| Evaluation | Drug | Modality | Dose | Route |
|---|---|---|---|---|
| Comparator | Human Embryonic Stem Cell-Derived Cardiomyocyte | Cell therapy | 5e+07 cells | — |
| Comparator | Human Embryonic Stem Cell-Derived Cardiomyocyte | Cell therapy | 1.5e+08 cells | — |
| Comparator | Human Embryonic Stem Cell-Derived Cardiomyocyte | Cell therapy | 3e+08 cells | — |